These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2482304)

  • 21. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
    le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
    Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
    Deano DA; Wu D; Mautner RK; Sherman RH; Ehsani AI; Rosen KM
    Chest; 1977 May; 71(5):597-606. PubMed ID: 856558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia.
    Rizos I; Brachmann J; Lengfelder W; Schmitt C; von Olshausen K; Kübler W; Senges J
    Eur Heart J; 1987 Feb; 8(2):154-63. PubMed ID: 3569310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhythmias of chagasic patients with advanced myocardial damage.
    Carrasco HA; Vicuña AV; Molina C; Landaeta A; Reynosa J; Vicuña N; Fuenmayor A; López F
    Int J Cardiol; 1985 Dec; 9(4):425-38. PubMed ID: 3908329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of intravenous disopyramide in acute cardiac arrhythmias.
    De Backer M; Stoupel E; Kahn RJ
    Eur J Clin Pharmacol; 1981 Jan; 19(1):11-8. PubMed ID: 6161824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
    Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Oral longterm therapy with disopyramide phosphate in patients with atrial and ventricular arrhythmias (author's transl)].
    Stauch M; Grewe N
    MMW Munch Med Wochenschr; 1977 Dec; 119(48):1563-6. PubMed ID: 74799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Action of injected disopyramide on ventricular arrhythmias and atrioventricular conduction].
    Vogel M; Desoutter P; Bellanger P; Motté G; Welti JJ
    Arch Mal Coeur Vaiss; 1976 Apr; 69(4):395-406. PubMed ID: 59581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.
    Au PK; Bhandari AK; Bream R; Schreck D; Siddiqi R; Rahimtoola SH
    J Am Coll Cardiol; 1987 Feb; 9(2):389-97. PubMed ID: 2433319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of disopyramide and mexiletine for better tolerance and additive effects for treatment of ventricular arrhythmias.
    Kim SG; Mercando AD; Tam S; Fisher JD
    J Am Coll Cardiol; 1989 Mar; 13(3):659-64. PubMed ID: 2918173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct enantiomeric resolution of disopyramide and its metabolite using chiral high-performance liquid chromatography. Application to stereoselective metabolism and pharmacokinetics of racemic disopyramide in man.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    J Chromatogr; 1988 Oct; 450(2):211-6. PubMed ID: 3235589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation.
    Lerman BB; Waxman HL; Buxton AE; Josephson ME
    Am J Cardiol; 1983 Mar; 51(5):759-64. PubMed ID: 6829435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolite in rabbits.
    Horikawa M; Yasumuro M; Kanno M; Hanada K; Hashiguchi M; Ogata H
    J Pharm Pharmacol; 2001 Dec; 53(12):1621-8. PubMed ID: 11804392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereoselective effects of disopyramide enantiomers in humans.
    Lima JJ; Boudoulas H
    J Cardiovasc Pharmacol; 1987 May; 9(5):594-600. PubMed ID: 2439842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disopyramide induced atypical ventricular tachycardia.
    Chia BL
    Aust N Z J Med; 1980 Dec; 10(6):665-8. PubMed ID: 6938189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical scope of disopyramide seven years after introduction--an overview.
    Willis PW
    Angiology; 1987 Feb; 38(2 Pt 2):165-73. PubMed ID: 2435196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.